Enapotamab vedotin Antibody
Enapotamab vedotin is an investigational AXL-targeting antibody-drug conjugate (ADC) delivering MMAE to disrupt microtubules. It shows potent activity in preclinical models of high-AXL NSCLC, including EGFR inhibitor-resistant tumors, supporting its study in both in vitro and in vivo oncology research.
Product Specifications
Product Name Alternative
HuMAX-AXL-ADC, EnaV, EnaV, HuMAX-AXL-ADC
Target
TAM Receptor, Antibody-Drug Conjugates (ADCs)
Clonality
Monoclonal
Conjugation
Unconjugated
Field of Research
Signal Transduction
Concentration
7.49 mg/mL
Purity
>95.0% (May vary between batches)
Molecular Weight
150.63 kDa
Storage Conditions
Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
Notes
For research use only.
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
LY427996 100 µg
RAB11FIP3 (NM_001142272) Human Over-expression Lysate
Sign In for Pricing
View Details 
